Most importantly, we have demonstrated that the treatment of mice with the ApoE antagonist OCTA significantly decreases the incidence of ECM and that OCTA has the potential to be used in the development of novel cerebral malaria adjunctive therapies. Here, APOE is linked to cerebral malaria.